Close

CVS Caremark (CVS) Tops Q2 EPS by 3c; Boosts FY14 EPS Midpoint Guidance

August 5, 2014 7:00 AM EDT

(Updated - August 5, 2014 7:10 AM EDT)

CVS Caremark (NYSE: CVS) reported Q2 EPS of $1.13, $0.03 better than the analyst estimate of $1.10. Revenue for the quarter came in at $34.6 billion versus the consensus estimate of $33.47 billion.

Same store sales increased 3.3% versus the second quarter of last year, with pharmacy same store sales up 5.0% and front store same store sales down 0.4%. Pharmacy same store prescription volumes rose 3.9% on a 30-day equivalent basis.

The Company raised and narrowed its earnings guidance range for the full year 2014. The Company now expects to deliver Adjusted EPS of $4.43 to $4.51, up from $4.36 to $4.50. Consensus expectations are at FY14 EPS of $4.46.

The Company expects to deliver Adjusted EPS of $1.11 to $1.14 and GAAP diluted EPS from continuing operations of $1.04 to $1.07 in the third quarter of 2014. The Street sees Q3 EPS of $1.13.

For earnings history and earnings-related data on CVS Caremark (CVS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance, Retail Sales

Related Entities

Earnings